The effect of Ellagic acid supplementation in patients with type 2 diabetes

The effect of ellagic acid supplementation on glycemic indices, lipid profile, anthropometric, inflammatory and oxidative indices, dietary intake and serum levels of pentosidine, adiponectin and resistin in patients with types 2: a double-blind, randomized controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121028011288N18

Enrollment

Registered

2022-10-26

Start date

2022-10-21

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Patients in this group will receive 1capsules of 250 milligrams of ellagic acid (product by Exir Gostar Espadana Co. and made in The Iran) for 8 consecutive weeks a

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients with type 2 diabetes Using blood sugar lowering medicine Age range of 30-60 years BMI in the range of 25-35 1 to 15 years duration of type 2 diabetes Tendecy of corporation

Exclusion criteria

Exclusion criteria: Use of corticosteroids, steroidal and non-steroidal anti-inflammatory drugs Prescribing insulin Suffering from chronic diseases such as heart failure, kidney, liver and thyroid disorders

Design outcomes

Primary

Measure	Time frame
Serum level of pentosidine. Timepoint: At the beginning of the study and 60 days later. Method of measurement: ELISA kit.;Serum level of adiponectin. Timepoint: At the beginning of the study and 60 days later. Method of measurement: ELISA kit.;Serum level of resistine. Timepoint: At the beginning of the study and 60 days later. Method of measurement: ELISA kit.;Fasting blood sugar. Timepoint: The beginning of the study and 60 days later. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: The beginning of the study and 60 days later. Method of measurement: Enzymatic kit.;Serum triglyceride. Timepoint: The beginning of the study and 60 days later. Method of measurement: Enzymatic kit.;HDL serum level. Timepoint: The beginning of the study and 60 days later. Method of measurement: Enzymatic kit.;LDL serum level. Timepoint: The beginning of the study and 60 days later. Method of measurement: Farid Wald's formula.;Serum insulin level. Timepoint: The beginning of the study and 60 days later. Method of measurement: ELISA kit.;Hemoglobin A1c. Timepoint: The beginning of the study and 60 days later. Method of measurement: ELISA kit.;Weight. Timepoint: The beginning of the study and 60 days later. Method of measurement: Digital scale.;Height. Timepoint: The beginning of the study and 60 days later. Method of measurement: Tape measure.	—

Measure

Time frame

Serum level of pentosidine. Timepoint: At the beginning of the study and 60 days later. Method of measurement: ELISA kit.;Serum level of adiponectin. Timepoint: At the beginning of the study and 60 days later. Method of measurement: ELISA kit.;Serum level of resistine. Timepoint: At the beginning of the study and 60 days later. Method of measurement: ELISA kit.;Fasting blood sugar. Timepoint: The beginning of the study and 60 days later. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: The beginning of the study and 60 days later. Method of measurement: Enzymatic kit.;Serum triglyceride. Timepoint: The beginning of the study and 60 days later. Method of measurement: Enzymatic kit.;HDL serum level. Timepoint: The beginning of the study and 60 days later. Method of measurement: Enzymatic kit.;LDL serum level. Timepoint: The beginning of the study and 60 days later. Method of measurement: Farid Wald's formula.;Serum insulin level. Timepoint: The beginning of the study and 60 days later. Method of measurement: ELISA kit.;Hemoglobin A1c. Timepoint: The beginning of the study and 60 days later. Method of measurement: ELISA kit.;Weight. Timepoint: The beginning of the study and 60 days later. Method of measurement: Digital scale.;Height. Timepoint: The beginning of the study and 60 days later. Method of measurement: Tape measure.

—

Secondary

Measure	Time frame
Energy intake level. Timepoint: At the beginning of the study and 60 days later. Method of measurement: 3-day Food Record Questionnaire.;Macronutrients intake level. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: 3-day Food Record Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAyda Najmi

Tabriz University of Medical Sciences

aydanjmy6@gmail.com0098 41 4793065

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026